Redcare Pharmacy stock trades in the low EUR 60s as analysts see significant upside
Published on 08/22/2026 at 12:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Redcare Pharmacy NV (ISIN NL0012044747) stock most recently closed on Xetra at EUR 63.45 on August 20, 2026, after a daily gain of 2.26 percent that highlighted renewed buying interest in the online pharmacy specialist.
Shares consolidate after recent Xetra move
Per one detailed European quote overview accessed on August 21, 2026, Redcare Pharmacy shares finished the August 20, 2026 Xetra session at EUR 63.45, marking a 2.26 percent advance on the day with a reported trading volume of 51,114 shares. This market snapshot also highlighted a 3.66 percent gain over the most recent five trading days, indicating that the stock has been drifting higher rather than retreating despite broader volatility in smaller German healthcare names.
Another SDAX performance overview for August 21, 2026 cited intraday levels for Redcare Pharmacy between EUR 61.90 and EUR 63.40, with a short-term setback of 2.44 percent at one point alongside declines in several other mid-cap constituents. This Frankfurt market report underlines that the shares can be volatile in day trading but are still holding in the low EUR 60s, close to the August 20, 2026 closing level used for many consensus calculations.
Consensus points to three-digit price potential
Recent consensus data compiled from multiple analyst models shows an average 12-month price target of EUR 86.10 for Redcare Pharmacy, using the August 20, 2026 closing price of EUR 63.45 as the reference. The same consensus table therefore implies an upside of EUR 22.65 per share between the average target and the actual market price, which translates into a discount of more than 35 percent relative to what covering analysts currently model as a fair value scenario.
A separate analyst aggregation dated August 22, 2025 but still useful as a historical comparison listed four positive and one negative rating for Redcare Pharmacy NV, with an average target of EUR 164.20 and a reference price of EUR 62.73 at that time. This older target overview illustrates how the stock has previously traded at levels significantly below the price objectives used in analyst valuation models, leaving room for rerating when fundamentals and growth prospects align with investor expectations.
For investors, the quantified spread between the current Xetra closing price in the low EUR 60s and consensus in the mid EUR 80s is one of the key narrative points: the implied upside of EUR 22.65 per share as of August 20, 2026 compares with the recent five-day gain of 3.66 percent, suggesting that the valuation gap has only begun to narrow.
Online pharmacy and healthcare services as growth engine
Redcare Pharmacy has evolved from a pure online pharmacy into a broader digital healthcare platform, combining prescription and over-the-counter medicines with health products and services delivered via e-commerce. This positioning in health care and online pharmacy and e-commerce, as reflected in recent market summaries, aligns the company with secular trends toward digital medication ordering, telehealth integration, and data-supported adherence programs.
In its most recent half-year results, management highlighted the path out of the loss zone both operationally and at the bottom line, emphasizing that the company is progressing toward sustainable profitability. One same-day commentary on the half-year balance sheet stressed that Redcare Pharmacy is on its way to reducing losses under the balance sheet line, using revenue growth and efficiency improvements to narrow the gap between operating performance and net income. These comments place the current stock consolidation against a backdrop of ongoing transformation rather than stagnation.
Historically, Redcare Pharmacy has used multi-year expansion in online pharmacy and healthcare services to scale its business, and the latest half-year figures signal that this scaling effort is beginning to affect margins and earnings. While exact revenue and earnings numbers from the latest period are not referenced in the current day-filtered sources, the qualitative description of progress toward profit supports the analyst view that the valuation discount at EUR 63.45 on August 20, 2026 could shrink further if the company continues to execute.
Representative product: Redcare online pharmacy platform
A representative product for Redcare Pharmacy is its core online pharmacy platform, which allows patients and consumers to order prescription medicines, over-the-counter drugs, and health products digitally with home delivery and integrated customer service. The platform typically supports electronic prescriptions, repeat-order functionality, and access to a broad catalog of branded and generic medicines, creating a scalable base for future growth in digital healthcare services across European markets.
Stock level and investor takeaway
As of August 20, 2026, the latest completed Xetra session shows Redcare Pharmacy stock at EUR 63.45, with that price serving as the anchor point for the daily gain of 2.26 percent, the five-day performance of 3.66 percent, and the consensus-implied upside of EUR 22.65 per share used in current valuation discussions.
Read more
Further details on Redcare Pharmacy stock, its recent Xetra performance, and the consensus valuation spread can be found in the extended market and corporate overview published on August 21, 2026. This material offers deeper context on trading volumes, historical performance ranges, and how analysts model the company’s transition toward improved profitability.
Fact box
Company: Redcare Pharmacy NV
ISIN: NL0012044747
Ticker: RDC
Exchange: Xetra
Price (as of August 20, 2026, 5:35 p.m. CET): EUR 63.45
Sector / Industry: Health care / Online pharmacy and e-commerce
Index membership: SDAX
